Neo Ivy Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-57,504
| Closed | -$1.06M | – | 272 |
|
|
2024
Q4 | $1.06M | Buy |
57,504
+54,022
| +1,551% | +$991K | 0.21% | 154 |
|
|
2024
Q3 | $54K | Sell |
3,482
-199,566
| -98% | -$3.09M | 0.02% | 245 |
|
|
2024
Q2 | $3.3M | Buy |
+203,048
| New | +$3.3M | 0.65% | 68 |
|
|
2023
Q4 | $0 | Buy |
+3
| New | – | ﹤0.01% | 276 |
|
|
2023
Q3 | – | Sell |
-36,483
| Closed | -$874K | – | 310 |
|
|
2023
Q2 | $874K | Buy |
+36,483
| New | +$874K | 0.46% | 70 |
|
|
2022
Q3 | – | Sell |
-324
| Closed | -$4K | – | 370 |
|
|
2022
Q2 | $4K | Sell |
324
-1,260
| -80% | -$15.6K | 0.01% | 357 |
|
|
2022
Q1 | $38K | Sell |
1,584
-1,682
| -52% | -$40.4K | 0.03% | 392 |
|
|
2021
Q4 | $76K | Buy |
+3,266
| New | +$76K | 0.11% | 246 |
|
|
2021
Q3 | – | Sell |
-252
| Closed | -$6K | – | 441 |
|
|
2021
Q2 | $6K | Sell |
252
-6,006
| -96% | -$143K | 0.01% | 404 |
|
|
2021
Q1 | $161K | Buy |
6,258
+1,979
| +46% | +$50.9K | 0.18% | 189 |
|
|
2020
Q4 | $229K | Buy |
4,279
+1,086
| +34% | +$58.1K | 0.26% | 141 |
|
|
2020
Q3 | $131K | Buy |
+3,193
| New | +$131K | 0.13% | 248 |
|
|
2020
Q2 | – | Sell |
-6,661
| Closed | -$281K | – | 442 |
|
|
2020
Q1 | $281K | Buy |
+6,661
| New | +$281K | 0.46% | 66 |
|
|
2019
Q3 | – | Sell |
-16,832
| Closed | -$450K | – | 274 |
|
|
2019
Q2 | $450K | Buy |
16,832
+14,391
| +590% | +$385K | 0.25% | 168 |
|
|
2019
Q1 | $65K | Buy |
+2,441
| New | +$65K | 0.04% | 244 |
|